<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04157621</url>
  </required_header>
  <id_info>
    <org_study_id>00073767</org_study_id>
    <nct_id>NCT04157621</nct_id>
  </id_info>
  <brief_title>taVNS in Mild to Moderate Parkinson's Disease</brief_title>
  <acronym>taVNS</acronym>
  <official_title>Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Mild to Moderate Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether a non-invasive form of nerve stimulation&#xD;
      called transcutaneous vagus nerve stimulation (taVNS) is safe and effective in people with&#xD;
      Parkinson's Disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2018</start_date>
  <completion_date type="Actual">June 15, 2021</completion_date>
  <primary_completion_date type="Actual">June 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Motor Function score as assessed by modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III</measure>
    <time_frame>Baseline (Visit 1) to Day 14 (Visit 10)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Function score</measure>
    <time_frame>Screening to Day 13 (Visit 9)</time_frame>
    <description>Delis-Kaplan Executive Function System (DKEFS) verbal fluency and switching</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Function score</measure>
    <time_frame>Screening to Day 13 (Visit 9)</time_frame>
    <description>Stroop written test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Function score</measure>
    <time_frame>Screening to Day 13 (Visit 9)</time_frame>
    <description>Digit symbol computer based</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Function score</measure>
    <time_frame>Screening to Day 13 (Visit 9)</time_frame>
    <description>Digit span forward and backwards</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Active taVNS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active taVNS</intervention_name>
    <description>Patients will be masked to transcutaneous stimulation of the auricular branch of the vagus nerve at the tragus</description>
    <arm_group_label>Active taVNS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Stimulation</intervention_name>
    <description>Sham stimulation involves identical perceptual threshold finding and stimulation parameters as active stimulation, with the exception of stimulation target. Sham stimulation will be delivered to the left earlobe, a target believed to have little to no vagal nerve innervation.</description>
    <arm_group_label>Sham Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 40-79 y&#xD;
&#xD;
          -  Idiopathic Parkinson's Disease Diagnosis&#xD;
&#xD;
          -  Disease Stage: Hoehn and Yahr stage 2-3&#xD;
&#xD;
          -  Patient requires a minimum of 3 doses of levodopa daily&#xD;
&#xD;
          -  Willingness to be videotaped&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Dementia or Montreal Cognitive Assessment score &lt;24&#xD;
&#xD;
          -  Parkinson's Disease psychosis&#xD;
&#xD;
          -  Ear trauma&#xD;
&#xD;
          -  Facial pain&#xD;
&#xD;
          -  Traumatic Brain Injury or clinical history of stroke&#xD;
&#xD;
          -  Metal implants above the shoulders&#xD;
&#xD;
          -  History of myocardial infarction or arrhythmia, bradycardia&#xD;
&#xD;
          -  Active respiratory disorder&#xD;
&#xD;
          -  Alcohol or substance use disorders&#xD;
&#xD;
          -  History of Deep Brain Stimulation (DBS) or other brain surgery&#xD;
&#xD;
          -  Epilepsy&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  B-Blockers, dopamine blocking agent, antiarrhythmic medication, acetylcholine esterase&#xD;
             inhibitor, midodrine, florinef, droxidopa, or anticholinergic drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vanessa Hinson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 9, 2019</study_first_submitted>
  <study_first_submitted_qc>November 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Vanessa Hinson</investigator_full_name>
    <investigator_title>Program Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

